Expression of HSP90 in gastrointestinal stromal tumours and mesenchymal tumours

Histopathology

Volumn 56, Issue 6, 2010, Pages 694-701

  Kang, Gu Hyun ^a   Lee, Eui Jin ^a   Jang, Ki Taek ^a   Kim, Kyoung Mee ^a   Park, Cheol Keun ^a   Lee, Choong Sik ^b   Kang, Dae Young ^b   Lee, Sug Hyung ^c   Sohn, Tae Sung ^a   Kim, Sung ^a  

^a Sungkyunkwan University   (South Korea)

^b Chungnam National University   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

Gastrointestinal stromal tumour; HSP90; Mesenchymal tumour; Prognosis

Indexed keywords

HEAT SHOCK PROTEIN 90; IMATINIB; STEM CELL FACTOR RECEPTOR;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CONTROLLED STUDY; DRUG TARGETING; FEMALE; FIBROMATOSIS; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SURGERY; GENE ACTIVATION; GENE DELETION; GENE DUPLICATION; GENE MUTATION; GENE OVEREXPRESSION; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MISSENSE MUTATION; MITOSIS; NERVE SHEATH TUMOR; NEURILEMOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; TUMOR LOCALIZATION; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING; GENETICS; METABOLISM; MIDDLE AGED; MUSCLE TUMOR; PATHOLOGY;

AGED; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; NEOPLASMS, MUSCLE TISSUE; NERVE SHEATH NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 77951731288     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03550.x     Document Type: Article

References (18)

1. Fletcher CD, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum. Pathol. 2002 33 459 465. (Pubitemid 34747864)
2. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J. Clin. Oncol. 2004 22 3813 3825.
3. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 2002 347 472 480.
4. Fletcher JA, Rubin BP. KIT mutations in GIST. Curr. Opin. Genet. Dev. 2007 17 3 7.
5. Bauer S, Yu LK, Demetri GD, Fletcher JA. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res. 2006 66 9153 9161.
6. Richter K, Hendershot LM, Freeman BC. The cellular world according to Hsp90. Nat. Struct. Mol. Biol. 2007 14 90 94.
7. Sreedhar AS, Kalmar E, Csermely P, Shen YF. Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett. 2004 562 11 15.
8. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat. Rev. 2005 5 761 772.
9. Neckers L, Ivy SP. Heat shock protein 90. Curr. Opin. Oncol. 2003 15 419 424.
10. Xu W, Neckers L. Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin. Cancer Res. 2007 13 1625 1629.
11. Wagner AJ, Morgan JA, Chugh R et al. Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: clinical results from phase I trial. J. Clin. Oncol. 2008 26 10503.
12. Hornick JL, Fletcher CD. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hum. Pathol. 2007 38 679 687.
13. Keun Park C, Lee EJ, Kim M et al. Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy. Ann. Surg. 2008 247 1011 1018.
14. Kang DY, Park CK, Choi JS et al. Multiple gastrointestinal stromal tumors: clinicopathologic and genetic analysis of 12 patients. Am. J. Surg. Pathol. 2007 31 224 232.
15. McCarthy MM, Pick E, Kluger Y et al. HSP90 as a marker of progression in melanoma. Ann. Oncol. 2008 19 590 594.
16. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005 10 86 103.
17. Chiosis G, Huezo H, Rosen N, Mimnaugh E, Whitesell L, Neckers L. 17AAG: low target binding affinity and potent cell activity-finding an explanation. Mol. Cancer Ther. 2003 2 123 129.
18. Nilsson B, Sjolund K, Kindblom LG et al. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br. J. Cancer 2007 96 1656 1658.